GRIN-related neurodevelopmental disorders
NMDA-receptor (GRIN) conditions where, as in SCN2A, the direction of the variant decides treatment — and targeted therapies are now in Phase 3.
GRIN-related neurodevelopmental disorders are caused by changes in the GRIN1, GRIN2A or GRIN2B genes, which build the NMDA receptor — a key channel for learning and brain development. They cause a spectrum of intellectual disability, autism, movement problems and epilepsy. As with SCN2A, the variant can make the receptor overactive (gain of function) or underactive (loss of function), and this direction determines which targeted treatment makes sense. For the first time, therapies matched to the mechanism have reached clinical trials.
At a glance
- Genes
- GRIN1, GRIN2A, GRIN2B (NMDA receptor)
- Features
- Intellectual disability, autism, movement disorder, epilepsy
- Two mechanisms
- Gain-of-function vs loss-of-function — opposite treatments
- Gain-of-function
- NMDA blockers; radiprodil in Phase 3
- Loss-of-function
- L-serine (NMDA co-agonist) studied
What GRIN disorders are
The NMDA receptor is central to how neurons communicate and how the brain learns and develops. GRIN genes build its subunits, so variants disturb brain development and signalling, producing a range that can include developmental delay, intellectual disability, autism, movement disorders and epilepsy of varying severity.
Gain- versus loss-of-function
Just as in SCN2A, GRIN variants split into two opposite groups, and telling them apart guides treatment: gain-of-function variants make the receptor overactive, while loss-of-function (including 'null') variants make it underactive. The right targeted approach is the opposite in each case — so a functional interpretation of the variant is central.
Reducing NMDA-receptor activity may help gain-of-function disease but would be the wrong direction for loss-of-function — and vice versa. Getting the genetic and functional classification right is essential before considering targeted treatment.
The genetic pipeline: precision therapy
Treatment is increasingly matched to the mechanism, and dedicated therapies have advanced quickly:
- Gain-of-function — radiprodil (GRIN Therapeutics) is a selective negative modulator of the GluN2B subunit that dials down the overactive receptor. After a positive Phase 1b study (Honeycomb), the global Phase 3 Beeline trial dosed its first patient in January 2026; radiprodil holds FDA Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations and EMA PRIME designation. NMDA-blocking medicines already in use (such as memantine or dextromethorphan) are also tried off-label for gain-of-function variants.
- Loss-of-function — here the receptor needs boosting rather than dampening: L-serine, a natural NMDA-receptor co-agonist, improved motor function, behaviour and quality of life in a Phase 2a study of children with loss-of-function (null) GRIN2B variants.
How an educational review can help
GRIN disorders hinge on the precise variant and whether it is gain- or loss-of-function, which can be confusing. An educational review can explain the genetic report and this distinction in plain language, and put the emerging targeted therapies in honest context. It is educational and does not replace your clinician's care.
Selected sources
- GRIN Therapeutics. Radiprodil: Phase 1b Honeycomb results and Phase 3 Beeline trial (first patient dosed 2026); FDA Breakthrough/Orphan/RPD and EMA PRIME designations.
- L-serine treatment in GRIN-related disorders due to null variants: Phase 2a study.
- Reviews of GRIN-related neurodevelopmental disorders and genotype-directed treatment.
Last reviewed: 2026-05-22
Related treatments
Have a report you want explained?
Share your child's records and our specialists will prepare a written educational review.
Start a ReviewZatay Medical provides independent educational reviews only. Our reports are not a diagnosis, treatment, or prescription, and do not replace care from your treating physician.